Philip Tagari

Philip Tagari is insitro’s chief scientific officer, leading a team of multidisciplinary scientists and engineers who are redefining disease biology and implementing novel approaches to dramatically speed the delivery of meaningful therapeutics to patients with grievous disease.

With more than 30 years of research and preclinical development experience, he brings expertise across neurobiology, metabolic disease, hematology/oncology, immunology and inflammation, cell and molecular biology, antibody discovery and biologics engineering, medicinal, peptide and oligonucleotide chemistry, analytical chemistry and biochemistry, structural biology, pharmacokinetics, safety pharmacology, laboratory automation and information technologies.

Prior to insitro, Philip spent a decade as vice president of research (therapeutic discovery) at Amgen Inc. During that time, his global teams advanced over 30 innovative molecules into clinical development and commercialization including Lumukras® (first-in-class KRASG12C inhibitor); Tarlatamab (DLL3 BiTE®); AMG133 (anti-obesity bispecific) and Efavaleukin alfa (AMG 592) a novel IL-2 mutein Fc fusion. He is a director of CQDM (Consortium Quebecois sur la Decouverte du Medicament; Quebec Consortium for Drug Discovery) and SAB member for BenchSci (biology machine learning), NutcrackeRx (mRNA therapeutics) ad Amberstone Biosciences (novel biologics).

Prior to joining Amgen in 1998, Philip was a research fellow at Merck Frosst (Canada) Inc, where he contributed to the discovery of Singulair® and Vioxx®, and performed basic research at McGill and Oxford Universities and the UK Medical Research Council.

Key Paper:
Functional arrays of human pluripotent stem cell-derived cardiac microtissues